ACA 2021 Virtual WC Program Book

Wednesday, February 3, 2021 11:00 A.M. – 12:30 P.M EST

A-2A Incorporating Clozapine into Treatment Regimen for Mentally Ill Offenders to Assist in the Reduction of Self-Injuries, Assaultive Behavior and Length of Stay in Restrictive Housing (CE, CME, YCE) TRACK – Physician/ Midlevel Clozapine is the only FDA approved medication for treatment-resistant schizophrenia. The requirement for weekly blood tests for safety monitoring limits its use to people who haven't responded to other treatments. National survey data from state correctional facilities indicates clozapine is infrequently used. We will report on how clozapine is associated with reduction in severe, recurrent self-injury, and the need for outside emergency treatment. We will also provide new data showing how clozapine is associated with reduction in assaults, disciplinary infractions and reductions in the length of stay in restrictive housing. This workshop will review barriers to clozapine use and offer practical, real world suggestions to overcome them. Learning Objectives : 1. Participants will be able to describe the potential benefits for clozapine use with treatment-resistant schizophrenia, and for non-psychotic patients. 2. Participants will understand how clozapine is different from other psychotropic medications in terms of what is required for safe and effective monitoring. 3. Participants will recognize barriers to clozapine use and learn practical suggestions to overcome these barriers. Moderator: Terri Catlett , PA, Director of Healthcare Administration, North Carolina Department of Public Safety-Prisons, Raleigh NC Speakers : Brian Sheitman , M.D., North Carolina Department of Public Safety, Raleigh, NC; Theodore Zarzar , M.D., UNC Chapel Hill Department of Psychiatry, Chapel Hill, NC; Joseph Williams , M.D., UNC Chapel Hill Department of Psychiatry, Chapel Hill, NC

A-2B Treating Alcohol Addiction from a Multidisciplinary Perspective (CE, CME, YCE, CERP) TRACK: Mental Health Alcohol is a drug that over time has gotten less attention in corrections. This may be due to the opioid overdoses and deaths and the resurgence of dangerous drugs such as Synthetic drugs and Methamphetamine. However, alcohol continues for some to be a “Gateway Drug” and it has the potential to wreak havoc in the lives of many of our inmates. This presentation will look at the disease from a “medical lens” and a “psychological lens”. As multiple symptoms emerge, a holistic assessment must be done to capture current problems and potential solutions. Participants will hear from a medical doctor and a psychologist on current issues for inmates and the need for a multidisciplinary approach for effective treatment. Topical discussions will include Promising components will be presented which will include: medical assistance, root causes of the disease, power of recovery stories, need for period of abstinence, need to build a life around sober supports and activities, need for cognitive based treatment and other adjunct therapies and the need for community linkage with aftercare planning. Learning Objectives : 1. Participants will identify key medical symptoms and physical outcomes of alcohol addiction. 2. Participants will be able to prepare key treatment components of alcohol addiction by addressing the root cause of the disease. 3. Participants will be able to describe the importance of aftercare in treating alcohol addiction. Speaker : Randy Shively , Ph.D., Director of Research and Clinical Development, Alvis, Columbus, Ohio; John Hagan , M.D., Medical Director, Health Authority, North Dakota A-2C Chronic Care Clinics During a Pandemic (CE, CME) TRACK: Nursing The correctional environment is a population filled with various disease entities. As medical and mental health professionals there must be assurance that upon admission there is a treatment plan initiated and discussed with the